Join the DDA or

Mylan issues EpiPen shortage statement

Problems likely to continue until Q4

September 19th 2018

Tagged: Clinical guidance news

By Ailsa Colquhoun

Mylan is warning dispensing GPs that, due to manufacturing problems, there is a shortage of EpiPen Adrenaline Auto-Injectors in the UK.

In a statement, Mylan anticipates supply will stabilise in the fourth quarter of 2018. However, it is important to note that currently supply from Pfizer continues to vary and, as such, may not always be available to order. Further supplies of alternative adrenaline auto-injector products Jext and Emerade are currently expected by the end of September.

0.3mg adrenaline auto-injectors:

  • Currently supplies are available of EpiPen 0.3mg via a stock management process. Dispensaries are allocated stock on a prescription-only basis and can place orders for up to a maximum of two EpiPen 0.3mg auto-injectors per prescription.
  • A limited volume of EpiPen 0.3mg auto-injectors are available with a February 2019 expiry date. This supply is not subject to the current prescription validation process.
  • Emerade also supply a 0.5mg adrenaline auto-injector.

0.15mg adrenaline auto-injectors:

  • EpiPen Jr 0.15mg adrenaline auto-injectors are also expected to remain out of stock, until the end of September.
  • Jext and Emerade 0.15mg adrenaline auto-injectors are currently unavailable. Additional supplies of Jext are expected shortlty, and Emerade by the end of September. However, supplies are likely to be limited.

 Further advice on auto-injectors is available via the Anaphylaxis UK website.

For all the latest news of the 2019 DDA annual conference...

Learn more